Filing Details
- Accession Number:
- 0001209191-16-090637
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-01-08 18:56:07
- Reporting Period:
- 2016-01-06
- Filing Date:
- 2016-01-08
- Accepted Time:
- 2016-01-08 18:56:07
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1479290 | Revance Therapeutics Inc. | RVNC | Pharmaceutical Preparations (2834) | 770551645 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1597578 | Curtis Ruegg | C/O Revance Therapeutics, Inc. 7555 Gateway Boulevard Newark CA 94560 | Evp, Technical Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2016-01-06 | 2,000 | $8.70 | 20,027 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-01-06 | 2,000 | $33.06 | 18,027 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2016-01-06 | 2,000 | $0.00 | 2,000 | $8.70 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 53,836 | 2023-05-26 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2015.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.94 to $33.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The shares subject to this Option vest in 48 equal monthly installments over 4 years following May 27, 2013.
Billionaire Hedge Funds
